This would suggest that the early induction of IL-10 in COVID-19 appears to be able to modify the course of the infection during the early stages of the disease, and certainly has implications for the therapeutic use of IL-10 in severe COVID-19 patients. The gene discussed is IL10; the disease is COVID-19.